Overview

Single Dose of Tranexamic Acid and Blood Loss, in Elderly Patients With Hip Fracture

Status:
Unknown status
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the hypothesis that single dose of tranexamic acid (TXA) preoperatively will lower blood loss and transfusion rate in elderly patients with hip fractures (intertrochanteric or Subcapital), that will be treated with intramedullary nailing and cemented hemiarthroplasty respectively. After application of inclusion and exclusion criteria, patients will be randomized in two groups. Group 1 will include patients that receive preoperatively single dose of TXA (15mg/kg) and Group 2 will include patients that receive normal saline (control group).
Phase:
Phase 2
Details
Lead Sponsor:
National and Kapodistrian University of Athens
Treatments:
Tranexamic Acid